Figure 3.

Effects of CYC27 on dyslipidemia. Data in (A,B) represent the serum total cholesterol (TC) and triglyceride (TG) levels during the seven week administration with the vehicle, CYC27 and Rosiglitazone, and in BKS mice treated with the vehicle. Data are expressed as mean ± SD (n = 8). BKS group ^## p < 0.01 and ^### p < 0.01 versus BKS db group * p < 0.05 and ** p < 0.01. BKS—vehicle-treated normal BKS mice; BKS db—vehicle-treated diabetic BKS db mice; Rosiglitazone—Rosiglitazone, 50 mg·kg⁻¹·day⁻¹ Rosiglitazone-treated BKS db mice; CYC27-50—50 mg·kg⁻¹·day⁻¹ CYC27-treated BKS db mice; CYC27-25—25 mg·kg⁻¹·day⁻¹ CYC27-treated BKS db mice.